

Influenza vaccines available for use in the 2020-2021 season

Manufacturer and Product Name	Sanofi Pasteur Fluzone Quadrivalent	Sanofi Pasteur Fluzone High-Dose Trivalent	GlaxoSmithKline Flulaval Tetra Quadrivalent
Vaccine Preparation	IIV4	IIV3-HD	IIV4
Vaccine Type	Inactivated quadrivalent (split virus)	Inactivated trivalent (split virus)	Inactivated quadrivalent (split virus)
Route of Administration	IM	IM	IM
Authorized Ages for Use	≥ 6 months	≥ 65 years	≥ 6 months
Antigen Content (for each vaccine strain)	15 ug HA/0.5 mL dose	60 ug HA/0.5ml dose	15 ug HA/0.5 mL dose
Adjuvant	No	No	No
Antibiotics (traces)	None	None	None
Egg Protein (traces)	Yes	Yes	Yes
Thimerosal	Yes (multi-dose vials only)	No	Yes (multi -dose vials only)
Post Puncture Shelf Life (MDV)	28 days	N/A	28 days

Refer to product monograph for composition of each vaccine, including non- medicinal ingredients

Adapted from NACI Appendix A: Characteristics of influenza vaccines authorized for use in Canada, 2020-2021 [NACI Statement on Seasonal Influenza Vaccine 2020](#)